Intravenous recombinant tissue plasminogen activator was first approved for the treatment of acute ischemic stroke in the United States in 1996. Thrombolytic therapy has been proven to be effective in acute ischemic stroke treatment and shown to improve long-term functional outcomes. Its use is associated with an increased risk of symptomatic intracerebral hemorrhage as well as orolingual angioedema. Our goal is to outline the management strategies for these postthrombolysis complications.
Tissue plasminogen activator for acute ischemic stroke. The national institute of neurological disorders and stroke rt-PA stroke study group. N Engl J Med. 1995;333(24):1581–1587.
2.
HackeWKasteMBluhmkiE. Thrombolysis with alteplase 3 to 4.5 hours after acute ischemic stroke. N Engl J Med. 2008;359(13):1317–1329.
3.
Del ZoppoGJSaverJLJauchECAdamsHPJr. Expansion of the time window for treatment of acute ischemic stroke with intravenous tissue plasminogen activator: a science advisory from the American Heart Association/American Stroke Association. Stroke. 2009;40(8):2945–2948.
4.
RosamondWFlegalKFridayG. Heart disease and stroke statistics—2007 update: a report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Circulation. 2007;115(5):e69–e171.
5.
DemaerschalkBMYipTR. Economic benefit of increasing utilization of intravenous tissue plasminogen activator for acute ischemic stroke in the United States. Stroke. 2005;36(11):2500–2503.
6.
BarberPAZhangJDemchukAMHillMDBuchanAM. Why are stroke patients excluded from TPA therapy? An analysis of patient eligibility. Neurology. 2001;56(8):1015–1020.
7.
DengYZReevesMJJacobsBS. IV tissue plasminogen activator use in acute stroke: experience from a statewide registry. Neurology. 2006;66(3):306–312.
8.
MillerDJSimpsonJRSilverB. Safety of thrombolysis in acute ischemic stroke: a review of complications, risk factors, and newer technologies. Neurohospitalist. 2011;1(3):138–147.
9.
BrownDLBarsanWGLisabethLDGalleryMEMorgensternLB. Survey of emergency physicians about recombinant tissue plasminogen activator for acute ischemic stroke. Ann Emerg Med. 2005;46(1):56–60.
10.
SaverJL. Hemorrhage after thrombolytic therapy for stroke: the clinically relevant number needed to harm. Stroke. 2007;38(8):2279–2283.
GebelJMBrottTGSilaCA. Decreased perihematomal edema in thrombolysis-related intracerebral hemorrhage compared with spontaneous intracerebral hemorrhage. Stroke. 2000;31(3):596–600.
13.
FugateJEKalimullahEAWijdicksEF. Angioedema after tPA: what neurointensivists should know. Neurocrit Care. 2012;16(3):440–443.
14.
EngelterSTFluriFBuitrago-TellezC. Life-threatening orolingual angioedema during thrombolysis in acute ischemic stroke. J Neurol. 2005;252(10):1167–1170.
15.
LansbergMGAlbersGWWijmanCA. Symptomatic intracerebral hemorrhage following thrombolytic therapy for acute ischemic stroke: a review of the risk factors. Cerebrovasc Dis. 2007;24(1):1–10.
16.
GrahamGD. Tissue plasminogen activator for acute ischemic stroke in clinical practice: a meta-analysis of safety data. Stroke. 2003;34(12):2847–2850.
17.
HackeWDonnanGFieschiC. Association of outcome with early stroke treatment: pooled analysis of ATLANTIS, ECASS, and NINDS rt-PA stroke trials. Lancet. 2004;363(9411):768–774.
18.
KaseCSFurlanAJWechslerLR. Cerebral hemorrhage after intra-arterial thrombolysis for ischemic stroke: the PROACT II trial. Neurology. 2001;57(9):1603–1610.
19.
MazighiMSerfatyJMLabreucheJ. Comparison of intravenous alteplase with a combined intravenous-endovascular approach in patients with stroke and confirmed arterial occlusion (RECANALISE study): a prospective cohort study. Lancet Neurol. 2009;8(9):802–809.
20.
SeetRCRabinsteinAA. Symptomatic intracranial hemorrhage following intravenous thrombolysis for acute ischemic stroke: a critical review of case definitions. Cerebrovasc Dis. 2012;34(2):106–114.
21.
FurlanAHigashidaRWechslerL. Intra-arterial prourokinase for acute ischemic stroke. The PROACT-II study: a randomized controlled trial. Prolyse in acute cerebral thromboembolism. JAMA. 1999;282(21):2003–2011.
22.
HackeWKasteMFieschiC. Intravenous thrombolysis with recombinant tissue plasminogen activator for acute hemispheric stroke. The European Cooperative Acute Stroke Study (ECASS). JAMA. 1995;274(13):1017–1025.
23.
HackeWKasteMFieschiC. Randomised double-blind placebo-controlled trial of thrombolytic therapy with intravenous alteplase in acute ischaemic stroke (ECASSII). Second European-Australasian Acute Stroke Study investigators. Lancet. 1998;352(9136):1245–1251.
24.
WahlgrenNAhmedNDavalosA. Thrombolysis with alteplase for acute ischaemic stroke in the Safe Implementation of Thrombolysis in Stroke-Monitoring Study (SITS-MOST): an observational study. Lancet. 2007;369(9558):275–282.
25.
AlbersGWThijsVNWechslerL. Magnetic resonance imaging profiles predict clinical response to early reperfusion: the Diffusion and Perfusion Imaging Evaluation for Understanding Stroke Evolution (DEFUSE) study. Ann Neurol. 2006;60(5):508–517.
26.
LongstrethWTJrKatzRTirschwellDL. Intravenous tissue plasminogen activator and stroke in the elderly. Am J Emerg Med. 2010;28(3):359–363.
27.
The NINDS t-PA Stroke Study Group. Intracerebral hemorrhage after intravenous t-PA therapy for ischemic stroke. Stroke. 1997;28(3):2109–2118.
28.
SylajaPNCoteRBuchanAMHillMD. Canadian Alteplase for Stroke Effectiveness Study (CASES) Investigators. Thrombolysis in patients older than 80 years with acute ischaemic stroke: Canadian Alteplase for Stroke Effectiveness Study. J Neurol Neurosurg Psychiatry. 2006;77(7):826–829.
29.
CucchiaraBKasnerSETanneD. Factors associated with intracerebral hemorrhage after thrombolytic therapy for ischemic stroke: pooled analysis of placebo data from the Stroke-Acute Ischemic NXY Treatment (SAINT) I and SAINT II Trials. Stroke. 2009;40(9):3067–3072.
30.
DemchukAMMorgensternLBKriegerDW. Serum glucose level and diabetes predict tissue plasminogen activator-related intracerebral hemorrhage in acute ischemic stroke. Stroke. 1999;30(1):34–39.
31.
TanneDKasnerSEDemchukAM. Markers of increased risk of intracerebral hemorrhage after intravenous recombinant tissue plasminogen activator therapy for acute ischemic stroke in clinical practice: the Multicenter rt-PA Stroke Survey. Circulation. 2002;105(14):1679–1685.
32.
TsivgoulisGFreyJLFlasterM. Pre-tissue plasminogen activator blood pressure levels and risk of symptomatic intracerebral hemorrhage. Stroke. 2009;40(11):3631–3634.
33.
DerexLHermierMAdeleineP. Clinical and imaging predictors of intracerebral haemorrhage in stroke patients treated with intravenous tissue plasminogen activator. J Neurol Neurosurg Psychiatry. 2005;76(1):70–75.
34.
HermannADzialowskiIKochRGahnG. Combined anti-platelet therapy with aspirin and clopidogrel: risk factor for thrombolysis-related intracerebral hemorrhage in acute ischemic stroke?J Neurol Sci. 2009;284(1-2):155–157.
35.
MarshEBGottesmanRFHillisAEUrrutiaVCLlinasRH. Serum creatinine may indicate risk of symptomatic intracranial hemorrhage after intravenous tissue plasminogen activator (IV tPA). Medicine (Baltimore). 2013;92(6):317–223.
36.
LydenPDZivanJA. Hemorrhagic transformation after cerebral ischemia: mechanisms and incidence. Cerebrovas Brain Metab Rev. 1993;5(1):1–16.
37.
BalamiJSSutherlandBABuchanAM. Complications associated with recombinant tissue plasminogen activator therapy for acute ischaemic stroke. CNS Neurol Disord Drug Targets. 2013;12(2):155–169.
MazyaMVAhmedNFordGA. Remote or extraischemic intracerebral hemorrhage—an uncommon complication of stroke thrombolysis: results from the safe implementation of treatments in stroke-international stroke thrombolysis register. Stroke. 2014;45(6):1657–1663.
40.
TrouillasPvon KummerR. Classification and pathogenesis of cerebral hemorrhages after thrombolysis in ischemic stroke. Stroke. 2006;37(2):556–561.
41.
HirohataMYoshitaMIshidaC. Clinical features of non-hypertensive lobar intracerebral hemorrhage related to cerebral amyloid angiopathy. Eur J Neurol. 2010;17(6):823–829.
42.
AttemsJLaudaFJellingerKA. Sporadic cerebral amyloid angiopathy is not a frequent cause of spontaneous brain hemorrhage. J Neurol. 2008;255(1):70–76.
43.
RamaiahSSYanB. Low-dose tissue plasminogen activator and standard-dose tissue plasminogen activator in acute ischemic stroke in Asian populations: a review. Cerebrovasc Dis. 2013;36(3):161–166.
44.
ChaoACLiuCKChenCH. Taiwan Thrombolytic Therapy for Acute Ischemic Stroke (TTT-AIS) Study Group. Different doses of recombinant tissue-type plasminogen activator for acute stroke in Chinese patients. Stroke. 2014;45(8):2359–2365.
45.
YamaguchiT. Alteplase at 0.6 mg/kg for acute ischemic stroke within 3 hours of onset: Japan Alteplase Clinical Trial (J-ACT). Stroke. 2006;37(7):1810–1815.
46.
MoriEMinematsuKNakagawaraJ. Effects of 0.6 mg/kg intravenous alteplase on vascular and clinical outcomes in middle cerebral artery occlusion. Japan Alteplase Clinical Trial II (J-ACT II). Stroke. 2010;41(3):461–465.
47.
NakagawaraJMinematsuKOkadaY. Thrombolysis with 0.6 mg/kg intravenous alteplase for acute ischemic stroke in routine clinical practice. The Japan post-Marketing Alteplase Registration Study (J-MARS). Stroke. 2010;41(3):1984–1989.
48.
JauchECSaverJLAdamsHPJr. Guidelines for the early management of patients with acute ischemic stroke: a guideline for healthcare professionals from the American Heart Association/American Stroke Association. Stroke. 2013;44(3):870–947.
49.
GoldsteinJNMarreroMMasrurS. Management of thrombolysis-associated symptomatic intracerebral hemorrhage. Arch Neurol. 2010;67(8):965–969.
BroderickJConnollySFeldmannE. Guidelines for the management of spontaneous intracerebral hemorrhage in adults: 2007 update: a guideline from the American Heart Association/ American Stroke Association Stroke Council, High Blood Pressure Research Council, and the Quality of Care and Outcomes in Research Interdisciplinary Working Group. Stroke. 2007;38(6):2001–2023.
53.
YaghiSEisenbergerAWilleyJZ. Symptomatic intracerebral hemorrhage in acute ischemic stroke after thrombolysis with intravenous recombinant tissue plasminogen activator: a review of natural history and treatment. JAMA Neurol. 2014;71(9):1181–1185.
54.
Liu-DeRykeXRhoneyD. Hemostatic therapy for the treatment of intracranial hemorrhage. Pharmacotherapy. 2008;28(4):485–495.
55.
PiriyawatPMorgensternLBYawnDHHallCEGrottaJC. Treatment of acute intracerebral hemorrhage with epsilon-aminocaproic acid: a pilot study. Neurocrit Care. 2004;1(1):47–51.
56.
FrenchKFWhiteJHoeschRE. Treatment of intracerebral hemorrhage with tranexamic acid after thrombolysis with tissue plasminogen activator. Neurocrit Care. 2012;17(1):107–111.
57.
HuttonBJosephLFergussonDMazerCDShapiroSTinmouthA. Risks of harms using antifibrinolytics in cardiac surgery: systematic review and network meta-analysis of randomized and observational studies. BMJ. 2012;345:e5798.
58.
LeeSBMannoEMLaytonKFWijdicksEF. Progression of warfarin-associated intracerebral hemorrhage after INR normalization with FFP. Neurology. 2006;67(7):1272–1274.
59.
DentaliFMarchesiCPierfranceschiMG. Safety of prothrombin complex concentrates for rapid anticoagulation reversal of vitamin K antagonists: a meta-analysis. Thromb Haemost. 2011;106(3):429–438.
60.
MorgensternLBHemphillJCIIIAndersonC. Guidelines for the management of spontaneous intracerebral hemorrhage: a guideline for healthcare professionals from the American Heart Association/American Stroke Association. Stroke. 2010;41(9):2108–2129.
61.
MahaffeyKWGrangerCBSloanMA. Neurosurgical evacuation of intracranial hemorrhage after thrombolytic therapy for acute myocardial infarction: experience from the GUSTO-I trial: Global Utilization of Streptokinase and Tissue-Plasminogen Activator (tPA) for Occluded Coronary Arteries. Am Heart J. 1999;138(3 pt 1):493–499.
62.
HillMDBuchanAM. Thrombolysis for acute ischemic stroke: results of the Canadian Alteplase for stroke effectiveness study. CMAJ. 2005;172(10):1307–1312.
63.
HillMDLyeTMossH. Hemi-orolingual angioedema and ACE inhibition after alteplase treatment of stroke. Neurology. 2003;60(9):1525–1527.
64.
EngelterSTFluriFBuitrago-TellezC. Life-threatening orolingual angioedema during thrombolysis in acute ischemic stroke. J Neurol. 2005;252(10):1167–1170.
65.
YayanJ. Onset of orolingual angioedema after treatment of acute brain Ischemia with Alteplase depends on the site of brain ischemia: a meta-analysis. N Am J Med Sci. 2013;5(10):589–593.
66.
LinSYTangSCTsaiLK. Orolingual angioedema after alteplase therapy of acute ischaemic stroke: incidence and risk of prior angiotensin-converting enzyme inhibitor use. Eur J Neurol. 2014;21(10):1285–1291.
67.
RudolfJGrondMSchmullingSNevelingMHeissW. Orolingual angioneurotic edema following therapy of acute ischemic stroke with alteplase. Neurology. 2000;55(4):599–600.
